These findings provide evidence that TP53 deficiency and TET2 loss cooperate to drive the development of AML and that the immunosuppressive microenvironment seen in such cases may be amenable to therapeutic blockade of TIGIT signaling. The gene discussed is TP53; the disease is acute myeloid leukemia.